☆ 4.6 Article

Minimally invasive versus open McKeown esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant PD-1 inhibitor plus chemotherapy

FRONTIERS IN ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study

Jun Liu et al.

Summary: This study assessed the use of neoadjuvant camrelizumab plus chemotherapy in patients with resectable esophageal squamous cell carcinoma. The results showed that this treatment approach had promising efficacy and acceptable toxicity, providing an effective option for patients.

INTERNATIONAL JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma

Weixiong Yang et al.

Summary: This study evaluated the safety and feasibility of using PD-1 blockade in combination with chemotherapy as neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma (ESCC). The results showed that this neoadjuvant treatment regimen had manageable side effects and induced an objective response in 90.5% of patients, demonstrating its antitumor efficacy in resectable ESCC.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Huilai Lv et al.

Summary: This study evaluated the efficacy and safety of neoadjuvant sintilimab plus chemotherapy in patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC). The results showed that this treatment approach achieved a good pathological complete response rate and had good tolerability.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer

Smita Sihag et al.

Summary: Esophagectomy following neoadjuvant immunotherapy and standard chemoradiotherapy for locally advanced esophageal cancer appears to be safe and feasible based on the preliminary experience. There were no significant differences in major complications risk, interval to surgery, and 30-day mortality between the two groups.

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2021)

添加到收藏夹

Article Oncology

Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments

Dongni Chen et al.

Summary: This study compared minimally invasive and open surgery approaches in treating ESCC patients who underwent neoadjuvant therapy. Results showed that MIE had shorter operative time, less intraoperative bleeding, and lower anastomotic leakage rate compared to open surgery. Overall survival and disease-free survival did not differ between the two approaches for patients receiving neoadjuvant chemotherapy, but for patients receiving neoadjuvant chemoradiotherapy, MIE showed significantly better overall survival rates.

BMC CANCER (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma

Dijian Shen et al.

Summary: The study evaluated the efficacy and safety of PD-1 inhibitor in neoadjuvant chemotherapy for locally advanced ESCC, showing a high pCR rate and R0 resection rate with low toxicity. Long-term efficacy of this novel treatment should be confirmed with longer follow-up and prospective trials.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

添加到收藏夹

Article Surgery

Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma A Randomized Clinical Trial

Hao Wang et al.

Summary: The study compared the safety and long-term survival outcomes of neoadjuvant chemoradiotherapy (nCRT) followed by minimally invasive esophagectomy (MIE) with neoadjuvant chemotherapy (nCT) followed by MIE for locally advanced esophageal squamous cell carcinoma (ESCC) patients. The initial results showed that nCRT followed by MIE had similar safety and better pathologic outcomes compared to nCT followed by MIE for treating locally advanced ESCC.

JAMA SURGERY (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial

Huiyan Luo et al.

Summary: The addition of camrelizumab to chemotherapy significantly improved overall survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma. This treatment strategy could enhance the overall survival rate of patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Respiratory System

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma

Zhigang Wu et al.

Summary: In patients with resectable ESCC, the rate of major pathologic response (MPR) reached 42.11% after treatment with neoadjuvant chemotherapy combined with immunotherapy (NACI). The use of the NACI regimen did not increase the occurrence of complications in neoadjuvant treatment and operation, and the regression rate of Sum of lesion diameter (SLD) has a certain guiding significance for the effect of immunotherapy.

JOURNAL OF THORACIC DISEASE (2021)

添加到收藏夹

Article Oncology

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Respiratory System

The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma

Seong Yong Park et al.

JOURNAL OF THORACIC DISEASE (2020)

添加到收藏夹

Article Oncology

Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and S-1 for Resectable Advanced Esophageal Cancer

Keiji Hayata et al.

ANTICANCER RESEARCH (2018)

添加到收藏夹

Article Surgery

Minimally Invasive Versus Open Esophageal Resection Three-year Follow-up of the Previously Reported Randomized Controlled Trial: the TIME Trial

Jennifer Straatman et al.

ANNALS OF SURGERY (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Outcomes With Open and Minimally Invasive Ivor Lewis Esophagectomy After Neoadjuvant Therapy

Luis F. Tapias et al.

ANNALS OF THORACIC SURGERY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals

Thomas W. Rice et al.

DISEASES OF THE ESOPHAGUS (2016)

添加到收藏夹

Article Oncology

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

Joel Shapiro et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Oesophageal carcinoma

Arjun Pennathur et al.

LANCET (2013)

添加到收藏夹

Article Oncology

A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)

Nobutoshi Ando et al.

ANNALS OF SURGICAL ONCOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial

Surya S. A. Y. Biere et al.

LANCET (2012)

添加到收藏夹

Article Medicine, General & Internal

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

P. van Hagen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Medicine, General & Internal

Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer

Suzanne L. Topalian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Oncology

Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation

LR Chirieac et al.

CANCER (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.